Novel Immunotherapy Shows Early Promise in Melanoma Resistant to PD-1 Blockade

(MedPage Today) — A fourth of patients with advanced melanoma that had progressed on anti-PD-(L)1 therapy responded to an investigational immune-system stimulant plus pembrolizumab (Keytruda), according to a small phase II study.
Ten of 40 patients…